Compare Robinhood Markets, Inc. (HOOD) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Robinhood Markets, Inc. trades at $99.9 (market cap $90.88B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Robinhood Markets, Inc. is far larger — about 93× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HOOD | MRVI | |
|---|---|---|
Market Cap | $90.88B | $977.37M |
Volume | 23,337,832 | 2,742,564 |
Sector | Financials | Health |
52-Week High | $147.08 | $9.00 |
52-Week Low | $65.16 | $2.83 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $97.42B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $110.52, up 1.19% with a neutral technical signal. The company shows strong fundamentals with 2025 revenue of $4.47B and net income of $1.88B, though valuation metrics remain elevated (P/E 48.9, P/S 20.61). Recent news highlights expansion into 24/7 trading and AI-powered features, while earnings show mixed quarterly performance with two beats and one miss in the last four quarters.
Analyst consensus remains bullish with 74% buy ratings and a $138.60 price target, representing 25% upside potential. Key risks include high valuation multiples, competitive pressures in online brokerage, and regulatory scrutiny. The company's transformation into a broader financial services platform provides growth opportunities but requires careful execution.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
